Antithrombotic Agent Use
Background
Antithrombotic agents are a crucial class of medications designed to prevent the formation of blood clots (thrombi) or to dissolve existing clots within the circulatory system. While blood clotting is a vital process to stop bleeding after injury, inappropriate or excessive clot formation can obstruct blood flow, leading to severe health complications. These agents are widely prescribed to manage and prevent a variety of cardiovascular and cerebrovascular diseases.
Biological Basis
Blood clot formation is a complex physiological process involving two primary mechanisms: platelet aggregation and the coagulation cascade. Platelets are cellular fragments that adhere to damaged blood vessel walls and clump together to form an initial plug. Subsequently, the coagulation cascade, a series of enzymatic reactions involving various clotting factors, converts fibrinogen into fibrin. This fibrin then forms a mesh-like structure that stabilizes the platelet plug, creating a robust clot. Antithrombotic agents exert their effects by targeting specific steps in these pathways. For example, antiplatelet drugs like aspirin inhibit platelet aggregation [1] while anticoagulants such as heparin interfere with the coagulation cascade. Fibrinolytic agents, including tissue plasminogen activator (tPA), actively work to break down existing fibrin clots. [1] Genetic variations in genes encoding key clotting factors, such as Factor VII (F7), plasminogen activator inhibitor-1 (SERPINE1 or PAI-1), and von Willebrand factor (vWF), can influence an individual's susceptibility to thrombosis and their response to antithrombotic therapies [1]
Clinical Relevance
Antithrombotic agents are indispensable in the prevention and treatment of numerous life-threatening conditions. These include myocardial infarction (heart attack), ischemic stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and complications arising from atrial fibrillation. Aspirin, for instance, is a common prescription for preventing recurrent cardiovascular events. [2] The efficacy and safety profile of these medications can vary substantially among individuals, often influenced by genetic predispositions that affect drug metabolism, the function of target proteins, and an individual's overall clotting tendency. Understanding these genetic factors is essential for personalizing treatment strategies, optimizing dosages, and minimizing potential adverse effects, such as bleeding complications.
Social Importance
Given the high prevalence of cardiovascular diseases worldwide, the use of antithrombotic agents holds immense social importance. These medications play a significant role in reducing global mortality and morbidity rates. However, the inherent risk of bleeding, a major side effect, necessitates careful patient monitoring and precise dose adjustments. Genetic insights offer a promising avenue for personalized medicine, enabling healthcare providers to predict an individual's likely response to therapy and their risk of adverse events. This tailored approach has the potential to improve patient outcomes, enhance treatment safety, and mitigate healthcare costs associated with complications.
Methodological and Statistical Constraints
The interpretability of findings from genome-wide association studies (GWAS) is significantly influenced by methodological and statistical constraints. Sample sizes, while often substantial, may still limit the power to detect genetic effects that explain only a modest proportion of phenotypic variation, especially when accounting for the extensive multiple testing burden inherent in GWAS. [3] This limitation can lead to an inflation of reported effect sizes for initially identified associations and necessitates rigorous replication in independent cohorts to validate true genetic signals. [4] Furthermore, the reliance on imputation for ungenotyped variants introduces a degree of uncertainty, with studies considering only SNPs imputed with relatively high confidence or meeting specific quality thresholds (e.g., RSQR ≥ 0.3 or estimated error rates of 1.46–2.14%). [5] The chosen SNP array density, such as 100K SNP platforms, may also provide incomplete coverage of genetic variation within specific gene regions, potentially leading to missed associations that could be detected with newer, denser arrays. [6] Therefore, many reported findings are considered hypotheses requiring further testing and validation.
Generalizability and Phenotypic Heterogeneity
The generalizability of genetic associations is constrained by the demographic characteristics of the study populations. Many large-scale GWAS, particularly in their initial phases, have predominantly involved individuals of European ancestry. [7] This demographic bias limits the direct applicability of findings to other ancestral groups, where allele frequencies, linkage disequilibrium patterns, and environmental exposures may differ, potentially influencing trait expression and treatment response. [8] Beyond ancestry, specific cohort inclusion and exclusion criteria, such as the exclusion of individuals on lipid-lowering therapies or aspirin for certain analyses, impact the study population and the observed genetic effects. [9] Phenotypic heterogeneity and measurement considerations also introduce limitations; while rigorous adjustments for covariates like age, sex, BMI, and smoking are performed, the decision to adjust for certain factors might mask or mediate genetic effects. [9] Additionally, the dynamic nature of some biomarkers, like C-reactive protein (CRP), necessitates careful consideration of acute-phase responses and the averaging of traits across multiple examinations to capture stable measures. [9]
Incomplete Understanding of Genetic Architecture and Environmental Influences
Despite significant advancements, GWAS still face limitations in fully elucidating the complex genetic architecture of traits and the role of environmental factors. Identified genetic variants, particularly cis-acting variants, often explain only a modest proportion of the total phenotypic variation (typically 1–10%), indicating a substantial "missing heritability" that may be attributed to rarer variants, complex epistatic interactions, or uncaptured environmental influences. [1] The interplay between genetic predispositions and environmental factors, known as gene-environment interactions, represents a critical but often unexplored area; for instance, associations of genes like ACE and AGTR2 with phenotypes can be modulated by dietary salt intake. [10] The absence of comprehensive investigations into these interactions means that the full context of genetic effects may not be appreciated. Furthermore, while GWAS can identify novel associations, interpreting their biological relevance remains a challenge, particularly for variants located in intergenic regions or those in genes not immediately apparent as related to the phenotype. [1] Therefore, many discovered associations serve as hypotheses that require further functional characterization and mechanistic studies to fully understand their impact.
Variants
Genetic variations play a crucial role in influencing an individual's susceptibility to cardiovascular disease and their response to antithrombotic agents. These variants affect a range of biological processes, from lipid metabolism and inflammation to blood coagulation and immune responses. Understanding these genetic predispositions can help personalize therapeutic strategies for preventing and managing thrombotic events.
Variations in genes involved in lipid metabolism significantly impact cardiovascular risk. The APOE gene encodes apolipoprotein E, a key protein in the transport and metabolism of fats, and its variant rs7412 (part of the APOE ε4 allele) is well-known for influencing cholesterol levels and increasing susceptibility to various diseases.. [11] Similarly, variants like rs12740374 in the CELSR2 gene, which is located near PSRC1 and SORT1, have been associated with altered lipid concentrations, particularly LDL cholesterol levels.. [11] The LPA gene, responsible for producing lipoprotein(a), is another critical player; elevated levels of this lipoprotein are a strong risk factor for atherosclerosis and thrombosis, and variants like rs74617384 and rs140570886 can influence its circulating concentration.. [7] Furthermore, the TRIB1 gene (represented by rs28601761) is recognized for its role in regulating triglyceride levels, with specific variants linked to dyslipidemia, thereby modulating overall cardiovascular risk.. [12] For individuals carrying these risk variants, antithrombotic agent use may be more critical or require adjusted dosages due to heightened thrombotic risk.
Inflammation and vascular integrity are also modulated by specific genetic variants. The CDKN2B-AS1 gene (also known as ANRIL), a long non-coding RNA, is located in a region frequently associated with coronary artery disease, with variants such as rs10757274 and rs1831733 implicated in cell cycle regulation and inflammatory processes within arterial walls. Similarly, the LINC01438 gene, represented by rs12639654 and rs1906596, is a long intergenic non-coding RNA that may play a regulatory role in gene expression relevant to vascular health and disease development. Variants in COL4A2, such as rs7989823, affect the structure and function of collagen type IV, a major component of basement membranes essential for vascular stability.. [4] These genetic factors can influence the progression of atherosclerosis and the likelihood of plaque rupture, making the appropriate selection and management of antithrombotic therapies vital to prevent events like myocardial infarction and stroke.. [6]
The ABO blood group system, determined by variants like rs532436 and rs545971, influences circulating levels of coagulation factors like Factor VIII and von Willebrand factor, thereby impacting an individual's risk for venous thromboembolism and arterial thrombosis.. [7] Distinct ABO blood types are associated with differing susceptibilities to thrombotic events, which may inform personalized antithrombotic strategies. The HLA-B gene, with variants like rs9266361 and rs9266344, is a critical component of the immune system; variations here can influence inflammatory responses that contribute to thrombotic risk and may also be relevant for drug hypersensitivity reactions to certain medications. The LDLR gene encodes the low-density lipoprotein receptor, vital for clearing LDL cholesterol from the bloodstream, and variants rs142158911 and rs73015016 can affect its efficiency, leading to altered lipid profiles. The adjacent SMARCA4 gene, involved in chromatin remodeling, might also have broader regulatory effects.. [1] Genetic insights from these loci can guide clinicians in assessing thrombotic risk and selecting appropriate antithrombotic agents, potentially optimizing treatment outcomes and minimizing adverse effects.
Key Variants
Conceptual Framework and Key Terminology of Hemostasis and Antithrombotic Action
Antithrombotic agents are a class of pharmacological substances designed to prevent or treat thrombosis by interfering with the complex processes of blood clot formation. [1] These agents encompass various mechanisms of action, including antiplatelet drugs like aspirin, which inhibits platelet aggregation, and anticoagulants such as heparin. [13] Thrombolytic agents, like streptokinase, tissue plasminogen activator (tPA), and anistreplase, are also part of this broader category, specifically used to dissolve existing clots in conditions like acute myocardial infarction. [13] The use of such agents, particularly aspirin, requires careful consideration in research, leading to the exclusion of individuals taking them from analyses of related hemostatic phenotypes to avoid confounding. [1]
Key terminology within this domain includes specific hemostatic factors such as fibrinogen, which is central to clot formation; PAI-1 (plasminogen activator inhibitor-1) and tPA, which regulate fibrinolysis; von Willebrand factor, crucial for platelet adhesion; and Factor VII (FVII), an initiator of the extrinsic coagulation pathway. [1] Hematological phenotypes, on the other hand, describe measurable characteristics of blood components, including red blood cell parameters like hematocrit (HCT), mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH), alongside platelet function assessments like platelet aggregation. [1] Understanding these terms is foundational for classifying and measuring the efficacy and impact of antithrombotic interventions.
Classification and Subtypes of Hemostatic and Hematological Phenotypes
Hemostatic and hematological phenotypes are broadly categorized based on their primary physiological roles, distinguishing between factors involved in coagulation and fibrinolysis (e.g., fibrinogen, PAI-1, tPA, FVII, von Willebrand factor) and those characterizing blood cell properties or platelet function (e.g., HCT, MCV, MCH, platelet aggregation). [1] Platelet aggregation, a critical aspect of primary hemostasis, is further subtyped by the specific agonists used to induce it, including adenosine diphosphate (ADP), collagen, and epinephrine (Epi), each eliciting distinct aggregation responses. [1] The response to arachidonic acid is also assessed, often as a categorical "yes/no" measure, providing insight into different pathways of platelet activation. [1]
These classifications allow for a granular understanding of the hemostatic system, enabling researchers to isolate and study specific pathways influenced by genetic variants or therapeutic agents. [1] For instance, the SERPINE1 gene encodes PAI-1, highlighting a genetic basis for variations in fibrinolytic capacity, while ITGB3 (integrin, beta 3, also known as platelet glycoprotein IIIa, antigen CD61) is integral to platelet aggregation. [1] Such detailed classification is essential for both clinical diagnostics and genome-wide association studies aiming to link genetic loci to specific hemostatic or hematological traits. [1]
Measurement Approaches and Diagnostic Criteria for Hemostatic Biomarkers
Precise measurement of hemostatic factors and hematological phenotypes relies on standardized laboratory methods and specific diagnostic criteria. [1] Plasma fibrinogen levels are typically quantified using the Clauss method, while antigens for PAI-1, tPA, von Willebrand factor, and FVII are assessed through enzyme-linked immunosorbent assays (ELISA). [1] Platelet aggregation is functionally evaluated using the Born method, which measures the percent extent of aggregation in response to varying concentrations of epinephrine and ADP, and the collagen lag time. [1] A categorical assessment of aggregation response to arachidonic acid is also performed. [1]
For hematological traits, HCT is determined by the Wintrobe method, involving centrifugation of blood and visual measurement against a calibrated scale. [1] Mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) are calculated ratios, representing the average volume and hemoglobin content of individual red blood cells, respectively, derived from HCT, hemoglobin (Hgb), and red blood cell count (RBCC). [1] In research contexts, these raw measurements are often transformed into standardized, multivariable-adjusted residuals to account for known covariates such as age, sex, body mass index, smoking status, blood pressure, and prevalent cardiovascular disease, ensuring robust statistical analyses. [1] Specific adjustments, such as adding 15 mmHg to systolic blood pressure and 10 mmHg to diastolic blood pressure for individuals on blood pressure medication, or log-transforming certain variables like triglycerides and C-reactive protein, further refine these measurements for accurate genetic association studies. [14]
Pharmacological Interventions for Antithrombotic Therapy
Pharmacological approaches are central to managing and preventing thrombotic events, involving various drug classes tailored to specific clinical scenarios. For instance, in acute myocardial infarction, studies have compared the efficacy of different thrombolytic agents such as streptokinase, tissue plasminogen activator (tPA), and anistreplase, often in conjunction with antiplatelet and anticoagulant therapies. [2] The combination of aspirin and heparin has been evaluated against aspirin alone in these acute settings, demonstrating the importance of structured treatment protocols. [2] Beyond acute care, low-dose aspirin has been studied for its role in the primary prevention of cardiovascular disease, particularly in women. [15] Additionally, medications like atorvastatin, while primarily targeting lipid levels, indirectly contribute to thrombotic risk reduction by addressing underlying cardiovascular risk factors. [16]
Lifestyle and Nutritional Strategies for Thrombotic Risk Reduction
Lifestyle and dietary modifications play a significant role in reducing the risk of developing a prothrombotic state. Research indicates a clear association between obesity and an increased prothrombotic state, highlighting weight management as a crucial preventive measure. [17] Nutritional interventions, such as those explored in studies like the Malmo Diet and Cancer Study and the SU.VI.MAX Study, investigate the impact of overall diet and specific micronutrients, including antioxidant vitamins and minerals, on cardiovascular health and cancer prevention. [18] Furthermore, genetic variations, such as common variants in the FADS1 FADS2 gene cluster, influence the fatty acid composition in phospholipids, suggesting that dietary fat intake interacts with genetic predispositions to affect thrombotic risk. [19] The antioxidant properties of naturally occurring compounds like uric acid have also been hypothesized to provide a defense against oxidative damage, which is implicated in processes leading to thrombosis. [20]
Preventive Screening and Risk Factor Modification
Effective prevention of thrombotic events involves comprehensive screening and aggressive modification of identified risk factors. Primary prevention strategies include the judicious use of agents like low-dose aspirin in at-risk populations, as demonstrated in trials evaluating its role in preventing cardiovascular disease in women. [15] Identifying and managing established cardiovascular risk factors, such as hypertension, dyslipidemia, and diabetes, is critical, as these factors contribute to the activation of coagulation and fibrinolysis observed in conditions like arteriosclerosis. [21] Genetic predispositions also contribute to an individual's thrombotic risk, with studies identifying genetic and environmental contributions to platelet aggregation and associations between common genetic variations in thrombosis genes and plasma hemostatic protein levels. [22] Monitoring markers like hemoglobin levels, which have been linked to the risk of cerebral infarction, further aids in early risk assessment and intervention. [23]
Clinical Monitoring and Treatment Protocols
Standardized clinical management protocols are essential for guiding the use of antithrombotic agents, ensuring patient safety and treatment efficacy. These protocols often involve systematic monitoring of coagulation and fibrinolytic markers, which can reveal the influence of conditions like atrial fibrillation on these systems in patients with cerebral infarction. [24] Regular assessment of hemostatic factors and hematological phenotypes, including platelet aggregation, provides crucial information for tailoring antithrombotic therapy and monitoring its effects. [1] In the context of acute coronary syndromes, detailed treatment algorithms compare different therapeutic approaches, such as the use of streptokinase versus tissue plasminogen activator, and the role of aspirin alone versus aspirin combined with heparin, to optimize patient outcomes. [2] Such structured approaches, informed by ongoing monitoring, enable clinicians to adjust dosages and agents as needed, minimizing adverse events while maximizing therapeutic benefits.
Genetic Insights and Future Directions
Advances in genetic research are continuously providing deeper insights into the predisposition for thrombotic disorders and related cardiovascular risk factors, paving the way for more personalized management strategies. Genome-wide association studies (GWAS) have identified common genetic variants associated with hemostatic factors and hematological phenotypes, offering a more comprehensive understanding of individual thrombotic risk. [1] For example, specific single nucleotide polymorphisms (SNPs) in genes like HMGCR are associated with low-density lipoprotein (LDL) cholesterol levels, and variations in ANGPTL4 can influence triglyceride and high-density lipoprotein (HDL) levels, both of which are critical for cardiovascular health. [8] These genetic insights can help identify individuals at higher risk for thrombotic events or those who might respond differently to antithrombotic agents, potentially guiding future precision medicine approaches. Such research also highlights how genetic factors, alongside environmental influences, contribute to complex traits like platelet aggregation and overall cardiovascular disease risk. [22]
Pharmacogenetics of Antithrombotic Agent Use
Pharmacogenetics explores how an individual's genetic makeup influences their response to medications, including antithrombotic agents. For these drugs, genetic variations can impact the efficacy of therapy, the risk of adverse reactions, and the overall hemostatic balance, which is the target of antithrombotic interventions. Understanding these genetic factors can help in personalizing treatment strategies.
Genetic Regulation of Coagulation Factors
Genetic variations play a significant role in determining the baseline levels of various coagulation factors, which are critical components of the hemostatic system and frequent targets for antithrombotic agents. For instance, a single nucleotide polymorphism (SNP), rs561241, located near the F7 gene, has been significantly associated with circulating levels of Factor VII (FVII), a key initiator of the extrinsic coagulation pathway. Similarly, variants such as rs6950982 and rs6956010 have been linked to plasminogen activator inhibitor-1 (PAI-1) levels, an important regulator of fibrinolysis, while the fibrinogen gene cluster (FGB, FGA, FGG) also harbors SNPs influencing fibrinogen levels, a central protein in clot formation . These factors participate in complex signaling cascades, where receptor activation on platelets and endothelial cells initiates intracellular signaling events, leading to the activation of coagulation enzymes and the formation of a fibrin clot. [21] Conversely, the fibrinolytic system, involving tPA and its inhibitor PAI-1, functions to dissolve clots, and dysregulation in this feedback loop, such as high PAI-1 and tPA levels, can precede acute myocardial infarction. [25]
The activation of platelets, a critical initial step in thrombosis, is influenced by both genetic and environmental factors. [6] Antithrombotic agents often target specific components of this process, for instance, by inhibiting receptor activation or downstream intracellular signaling cascades that lead to platelet aggregation. The coagulation cascade itself involves a series of proteolytic activations, where each activated factor serves as an enzyme to activate the next, culminating in thrombin generation and fibrin formation. This cascade is subject to various regulatory mechanisms, including protein modifications and allosteric control, ensuring that clot formation is localized and controlled. [21] Genetic variations in these hemostatic genes can influence plasma protein levels and cardiovascular disease risk, highlighting the importance of individual differences in response to antithrombotic therapies. [13]
Metabolic Pathways and Thrombotic Risk
Dysregulation in metabolic pathways, particularly lipid metabolism, significantly contributes to the prothrombotic state and cardiovascular disease. The mevalonate pathway, central to cholesterol biosynthesis, involves enzymes like 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase), whose activity and degradation rate are subject to complex regulation, including oligomerization state. [26] Genetic variants, such as common SNPs in HMGCR, have been found to affect alternative splicing of exon 13, influencing LDL-cholesterol levels. [8] Furthermore, genes like ANGPTL3 and ANGPTL4 regulate lipid metabolism, with variations in ANGPTL4 specifically shown to reduce triglycerides and increase HDL. [27]
These metabolic pathways are not isolated but interact with hemostatic mechanisms. For instance, obesity is associated with a prothrombotic state [17] suggesting metabolic regulation and flux control within adipocytes and hepatocytes can indirectly impact coagulation factors. The integration of lipid profiles with thrombotic markers is crucial, as common genetic variants at multiple loci contribute to polygenic dyslipidemia [13] which in turn exacerbates the risk of coronary artery disease. [5] Antithrombotic strategies may therefore include agents that not only directly affect coagulation but also modulate lipid metabolism to reduce overall thrombotic burden by addressing underlying metabolic dysregulation.
Cellular Signaling and Inflammatory Crosstalk
Cellular signaling pathways play a critical role in mediating the interactions between the vascular endothelium, platelets, and inflammatory cells, collectively contributing to thrombotic processes. The mitogen-activated protein kinase (MAPK) pathway, for example, is a fundamental intracellular signaling cascade involved in cellular responses to various stimuli, and its activation can influence vascular function. [10] Similarly, the cGMP signaling pathway, often targeted by vasodilators, can be antagonized by factors like angiotensin II, which increases phosphodiesterase 5A expression in vascular smooth muscle cells. [28] These signaling events are subject to hierarchical regulation, where initial receptor activation triggers a cascade of phosphorylation events, ultimately impacting gene expression and cellular behavior.
Inflammation is deeply intertwined with thrombotic mechanisms, forming a vicious cycle in conditions like atherosclerosis. Intercellular adhesion molecule-1 (ICAM-1), a marker of endothelial activation, is upregulated by thrombin in monocytes [29] demonstrating a direct link between coagulation and inflammatory signaling. Soluble ICAM-1 has a differential effect on the progression of atherosclerosis versus arterial thrombosis [30] highlighting the complex interplay at a systems level. The emergent properties of these network interactions mean that dysregulation in one pathway, such as chronic inflammation, can trigger or amplify prothrombotic states, necessitating antithrombotic agents that can also modulate inflammatory signaling or mitigate its downstream effects.
Genetic and Post-Translational Modifiers
Genetic variations and post-translational modifications are crucial regulatory mechanisms that profoundly influence the function and abundance of proteins involved in antithrombotic pathways. Gene regulation, including transcriptional control, dictates the baseline expression levels of key hemostatic factors. Beyond transcription, alternative splicing of pre-mRNA offers a sophisticated layer of post-transcriptional regulation, allowing a single gene to produce multiple protein isoforms with potentially different functions. [31] For example, common SNPs in HMGCR affect its alternative splicing, impacting its role in cholesterol metabolism [8] and alternative splicing of APOB mRNA can generate novel isoforms. [32]
Once proteins are synthesized, post-translational modifications, such as phosphorylation, glycosylation, and ubiquitination, can alter their activity, stability, and cellular localization. For instance, the oligomerization state influences the degradation rate of HMG-CoA reductase [26] demonstrating how structural changes impact protein turnover. Allosteric control, where binding of a molecule at one site affects activity at another, is a common mechanism for regulating enzyme function in both metabolic and signaling pathways. Understanding these regulatory mechanisms, from gene variants to protein modifications, is essential for identifying novel therapeutic targets and predicting individual responses to antithrombotic agents, especially in contexts of pathway dysregulation and compensatory mechanisms observed in disease states.
Risk Stratification and Prognostic Value in Cardiovascular Disease
Elevated circulating levels of hemostatic factors such as fibrinogen, plasminogen activator inhibitor-1 (SERPINE1), von Willebrand factor (VWF), tissue plasminogen activator (PLAT), factor VII (F7), and D-dimer are significantly associated with an increased risk of atherothrombosis, coronary heart disease (CHD), stroke, and other cardiovascular disease (CVD) events. [1] These markers provide crucial prognostic value, as high levels of plasminogen activator inhibitor-1 and tissue plasminogen activator, for instance, have been shown to precede a first acute myocardial infarction, highlighting their utility in identifying individuals at heightened risk for future cardiovascular events. [25] Similarly, von Willebrand factor in plasma serves as a risk factor for recurrent myocardial infarction and mortality, indicating its long-term prognostic implications for patient outcomes. [33]
Understanding the genetic and environmental contributions to hemostatic factors, such as platelet aggregation, is vital for personalized medicine approaches and prevention strategies. [6] Genome-wide association studies have identified specific single nucleotide polymorphisms (SNPs), such as rs561241 near the F7 gene, that are strongly associated with circulating factor VII levels, offering insights into inter-individual variability in hemostasis. [1] This genetic information, combined with assessment of elevated hemostatic factors, can refine risk stratification beyond traditional risk factors, allowing for more targeted primary and secondary prevention strategies for high-risk individuals. [13]
Clinical Applications in Treatment and Monitoring
The precise measurement of hemostatic factors and hematological phenotypes is fundamental for guiding treatment decisions and monitoring patient response to antithrombotic therapies. For example, in acute myocardial infarction, randomized comparisons of thrombolytic agents like streptokinase, tissue plasminogen activator, and anistreplase, alongside aspirin and heparin regimens, underscore the need for tailored therapeutic approaches based on individual patient profiles and disease severity. [2] Monitoring coagulo-fibrinolytic markers is also important in conditions like cerebral infarction, especially in patients with atrial fibrillation, to assess the efficacy of antithrombotic agents and adjust treatment to prevent further thrombotic events. [24]
Diagnostic evaluation of hemostatic function, including measures of fibrinogen, platelet aggregation, and red blood cell characteristics, can help identify a prothrombotic state in patients, such as those with arteriosclerosis or obesity. [21] This diagnostic utility extends to recognizing hemorheological disturbances in chronic cerebrovascular diseases, which may influence treatment choices. [34] Incorporating genetic insights into common variants in thrombosis-related genes may further personalize diagnostic assessments and treatment selection, optimizing outcomes by matching therapy to a patient's genetic predisposition to hemostatic dysfunction. [13]
Hemostatic Factors, Comorbidities, and Disease Associations
The interplay between hemostatic factors and various comorbidities is significant in the context of antithrombotic agent use. Conditions such as arteriosclerosis are characterized by activated coagulation and fibrinolysis, necessitating careful consideration of antithrombotic strategies. [21] Similarly, atrial fibrillation influences coagulo-fibrinolytic markers in patients with cerebral infarction, indicating a complex relationship where an underlying cardiac arrhythmia exacerbates thrombotic risk. [24] Obesity has also been linked to a prothrombotic state, underscoring the importance of addressing metabolic comorbidities when managing thrombotic risk. [17]
Hemostatic and hematological phenotypes are not isolated but are integral to broader systemic health. For instance, hemoglobin levels are associated with the risk of cerebral infarction, highlighting how seemingly distinct hematological parameters can have profound cardiovascular implications. [23] Hemorheological disturbances, which involve the flow properties of blood, are observed in chronic cerebrovascular diseases and contribute to disease progression, suggesting that antithrombotic interventions must consider the broader physiological context and potential syndromic presentations of thrombotic risk. [34] Genetic variations influencing hemostatic factors, identified through genome-wide association studies, further elucidate the polygenic nature of these associations and their contribution to overall cardiovascular health. [1]
References
[1] Yang Q, et al. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Medical Genetics, vol. 8, no. Suppl 1, 2007, p. S12.
[2] ISIS-3 Collaborative Group. "ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction." Lancet, vol. 339, 1992, pp. 753–770.
[3] Pe'er, Itsik, et al. "Estimation of the multiple testing burden for genomewide association studies of nearly all common variants." Genetic Epidemiology, vol. 32, no. 5, 2008, pp. 381-385.
[4] Benjamin, E. J., et al. "Genome-wide association with select biomarker traits in the Framingham Heart Study." BMC Med Genet, vol. 8, no. Suppl 1, 2007, p. S11.
[5] Willer, C. J., et al. "Newly identified loci that influence lipid concentrations and risk of coronary artery disease." Nature Genetics 40 (2008): 161-169.
[6] O'Donnell, C. J., et al. "Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study." BMC Med Genet, vol. 8, no. Suppl 1, 2007, p. S12.
[7] Melzer, D., et al. "A genome-wide association study identifies protein quantitative trait loci (pQTLs)." PLoS Genet, vol. 4, no. 5, 2008, p. e1000072.
[8] Burkhardt, R., et al. "Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13." Arteriosclerosis, Thrombosis, and Vascular Biology (2009).
[9] Ridker, Paul M., et al. "Loci Related to Metabolic-Syndrome Pathways Including LEPR, HNF1A, IL6R, and GCKR Associate with Plasma C-Reactive Protein: The Women's Genome Health Study." American Journal of Human Genetics, vol. 82, no. 5, 2008, pp. 1101-1112.
[10] Vasan, Ramachandran S., et al. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Medical Genetics, vol. 8, no. Suppl 1, 2007, p. S2.
[11] Kathiresan, S et al. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nat Genet, vol. 41, 2009, pp. 56-65.
[12] Aulchenko, Y. S., et al. "Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts." Nat Genet, vol. 41, no. 1, 2009, pp. 47-55.
[13] Kathiresan S, Yang Q, Larson MG, Camargo AL, Tofler GH, Hirschhorn JN, Gabriel SB, O'Donnell CJ: Common Genetic Variation in Five Thrombosis Genes and Relations to Plasma Hemostatic Protein Level and Cardiovascular Disease Risk. Arterioscler Thromb Vasc Biol 2006, 26:1405-1412.
[14] Sabatti C, et al. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nat Genet, vol. 41, no. 1, Jan. 2009, pp. 35-46.
[15] Ridker, P. M., et al. "A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women." New England Journal of Medicine 352 (2005): 1293-1304.
[16] Kajinami, K., et al. "ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin." Journal of Lipid Research 45 (2004): 653-656.
[17] Rosito GA, D'Agostino RB, Massaro J, Lipinska I, Mittleman MA, Sutherland P, Wilson PW, Levy D, Muller JE, Tofler GH: Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 2004, 91:683-689.
[18] Berglund, G., et al. "The Malmo Diet and Cancer Study. Design and feasibility." Journal of Internal Medicine 233 (1993): 45-51.
[19] Schaeffer, L., et al. "Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids." Human Molecular Genetics 15 (2006): 1745-1756.
[20] Ames, Bruce N., et al. "Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis." Proceedings of the National Academy of Sciences U S A 78 (1981): 6858-6862.
[21] Speiser W, Speiser P, Minar E, Korninger C, Niessner H, Huber K, Schernthaner G, Ehringer H, Lechner K: Activation of coagulation and fibrinolysis in patients with arteriosclerosis: relation to localization of vessel disease and risk factors. Thromb Res 1990.
[22] O'Donnell CJ, Larson MG, Feng D, Sutherland PA, Lindpaintner K, Myers RH, D'Agostino RA, Levy D, Tofler GH: Genetic and Environmental Contributions to Platelet Aggregation : The Framingham Heart Study. Circulation 2001, 103:3051-3056.
[23] Kannel WB, Gordon T, Wolf PA, McNamara P: Hemoglobin and the risk of cerebral infarction: the Framingham Study. Stroke 1972, 3:409-420.
[24] Ono N, Koyama T, Suehiro A, Oku K, Fujikake K, Kakishita E: Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction. Int Angiol 1992, 11:298-303.
[25] Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G: High Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma Precede a First Acute Myocardial Infarction in Both Men and Women : Evidence for the Fibrinolytic System as an Independent Primary Risk Factor. Circulation 1998, 98:2241-2247.
[26] Cheng, HH et al. "Oligomerization state influences the degradation rate of 3-hydroxy-3-methylglutaryl-CoA reductase." J Biol Chem, vol. 274, 1999, pp. 17171-17178.
[27] Koishi, R et al. "Angptl3 regulates lipid metabolism in mice." Nat Genet, vol. 30, 2002, pp. 151–157.
[28] Kim, D et al. "Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling." J Mol Cell Cardiol, vol. 38, 2005, pp. 175-184.
[29] Clark, P et al. "Intercellular adhesion molecule-1 (ICAM-1) expression is upregulated by thrombin in human monocytes and THP-1 cells in vitro and in pregnant subjects in vivo." Thromb Haemost, vol. 89, 2003, pp. 1043–1051.
[30] Albert, MA et al. "Differential effect of soluble intercellular adhesion molecule-1 on the progression of atherosclerosis as compared to arterial thrombosis: A prospective analysis of the Women’s Health Study." Atherosclerosis, 2007.
[31] Matlin, AJ et al. "Understanding alternative splicing: towards a cellular code." Nat Rev Mol Cell Biol, vol. 6, 2005, pp. 386–398.
[32] Khoo, B et al. "Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB." BMC Mol Biol, vol. 8, 2007, p. 3.
[33] Jansson JH, Nilsson TK, Johnson O: von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991, 66:351-355.
[34] Szapary L, Horvath B, Marton Z, Alexy T, Demeter N, Szots M, Klabuzai A, Kesmarky G, Juricskay I, Gaal V, et al.: Hemorheological disturbances in patients with chronic cerebrovascular diseases. Clin Hemorheol Microcirc 2004, 31:1-9.